Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Filing tables
Filing exhibits
- 20-F Annual report (foreign)
- 4.3 License Agreement Dated March 30, 2017, by and Between the Company and Yissum Research Development Company of the Hebrew University of Jerusalem LTD.
- 4.12 Form of Indemnification Agreement
- 12.1 Certification of the Chief Executive Officer Pursuant to Rule 13A-14(A) of the Securities Exchange Act of 1934
- 12.2 Certification of the Principal Financial and Accounting Officer Pursuant to Rule 13A-14(A) of the Securities Exchange Act of 1934
- 13.1 Certification of the Chief Executive Officer Pursuant to 18 U.s.c. 1350
- 13.2 Certification of the Principal Financial and Accounting Officer Pursuant to 18 U.s.c. 1350
SPRC similar filings
Filing view
External links
Exhibit 13.1
CERTIFICATION PURSUANT TO
18 U.S.C. Section 1350
In connection with the filing of the Annual Report on Form 20-F for the period ended December 31, 2016 (the “Report”) by Therapix Biosciences Ltd. (the "Company"), the undersigned, as Chief Executive Officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
(1) | the Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934; and |
(2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: May 1, 2017 | /s/ Elran Haber |
Name: Dr. Elran Haber | |
Title: Chief Executive Officer |